We are pleased to share Wellnex Life (ASX: WNX), owner and developer of some of Australia's leading health brands, has recently released a key ASX announcement.
Wellnex Life Limited (ASX: WNX) (“Wellnex” or “the Company”) is pleased to provide a trading update for the period January to April 2025 (the “Period”).
Announcement Highlights
1.Revenue for the Period of $8.0 million represents an increase of 46% compared to the same period 12 months earlier (“PCP”) of $5.4 million
2. Gross margins for the Period of $2.99 million, an increase of 55% on PCP of $1.93 million
3. Revenue for April 2025 was up 75% to $2.57 million compared to April 2024, with an equivalent growth in gross margins of 74% from $0.48 million to $1.13 million
4. Revenue for FY25 to April was $19.9 million with gross margins of $5.7 million, despite a previously disclosed slower than anticipated start to 2025and a strategic increase in trade investment in 1H FY25 reducing gross margins
5. Successful admission on 21 March 2025 to the AIM Market of the London Stock Exchange (“AIM”), with funds used to extinguish circa $13 million in debt with direct savings of circ $1.4 million in annual costs
Commenting on the progress,
Wellnex Life's Joint CEO Director Zack Bozinovski said:
"We continue to see growth across the whole business in both brands and IP licensing opportunities and we are confident that this will continue, which we expect to enhance the future performance of the business. With the recent completion of the dual listing on the AIM Market and the removal of c. $13 million in liabilities, the Company is well positioned to take advantage of the opportunities in the growing consumer healthcare market."
Read the full Wellnex Life ASX announcement here.
To learn more about Wellnex Life and stay up to date with investor information, subscribe to the Company's Chairman’s List.
